{'fraction_non_alphanumeric': 0.042606516290726815, 'fraction_numerical': 0.006265664160401002, 'mean_word_length': 5.099236641221374, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical Significance of Anti‐Ata

Ata is a high‐frequency red blood cell (RBC) antigen. Anti‐Ata has been reported in rare At(a–) black subjects. We report two cases of anti‐Ata. A clinically significant anti‐Ata was found in a 26‐year‐old black woman with systemic lupus erythematosus. The patient had a transfusion reaction with chills and nausea during a RBC survival study, and 95% of the radiolabeled At(a+) RBCs were destroyed within 3 h. A concurrently performed monocyte monolayer assay was strongly reactive. Anti‐Ata thus can cause rapid hemolysis of transfused RBCs, but At(a–) donor units are extremely scarce in rare donor registries. A second patient at our hospital had anti‐Ata which did not affect her newborn. She also had autoimmune disease, insulin‐dependent diabetes mellitus.